Every 8-K that OneMedNet Corp (ONMD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ONMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ONMD filings page.
OneMedNet Corporation has set September 18, 2026 as the date of its 2026 Annual Meeting of Stockholders, with August 11, 2026 as the record date for stockholders entitled to notice of and to vote at the meeting.
Stockholder proposals for inclusion in the company’s proxy materials, other stockholder proposals, and nominations of director candidates must all be received by the Secretary of the company no later than August 5, 2026, in accordance with SEC Rule 14a-8, SEC Rule 14a-19 for any director election contest, and the company’s Bylaws.
OneMedNet Corporation entered into a Standby Equity Purchase Agreement with YA II PN, Ltd. that allows the company, at its option, to sell up to $25 million of common stock over time. Sales can begin only after a resale registration statement for these shares becomes effective.
The agreement runs for 36 months. Each advance is limited to the greater of 500,000 shares and 100% of the stock’s five-day average trading volume, and is priced at 97% of the Market Price as defined in the agreement. Yorkville cannot exceed 4.99% beneficial ownership and, absent shareholder approval, total issuances are capped at 11,386,834 shares, which the company states is 19.99% of the 56,952,652 shares outstanding as of June 30, 2026.
OneMedNet Corporation reported that Nasdaq has notified the company its common stock no longer meets the $1.00 minimum bid price requirement, after trading below that level for 30 consecutive business days. The company has 180 days, until October 12, 2026, to regain compliance by having its share price at or above $1.00 for at least ten consecutive business days. If it still does not comply, OneMedNet may qualify for an additional 180-day period if it meets other Nasdaq Capital Market listing standards and commits to a plan that may include a reverse stock split. The company notes there is no assurance it will regain or maintain compliance, and failure to do so could result in Nasdaq delisting its shares.
OneMedNet Corporation announced that director Jair Clarke will not stand for re-election at the Company’s 2025 Annual Meeting of Stockholders. The Company stated his decision was not due to any disagreement with the Company or management. Mr. Clarke will remain on the Board until the Annual Meeting and will continue to serve in an advisory capacity thereafter.
OneMedNet Corporation reported that it has regained compliance with Nasdaq’s minimum bid price requirement for continued listing on The Nasdaq Capital Market. Nasdaq staff notified the company that, for 10 consecutive business days from September 24, 2025 through October 7, 2025, the closing bid price of its common stock was at least $1.00 per share, satisfying Nasdaq Listing Rule 5550(a)(2). With this notice, the prior bid price deficiency has been resolved and the listing compliance matter is now closed.
OneMedNet Corporation has regained compliance with Nasdaq’s continued listing standards. The company previously received a notice on March 12, 2025 stating that its market value of listed securities had fallen below the required $35,000,000 threshold under Nasdaq Listing Rule 5550(b)(2).
Nasdaq staff has now notified OneMedNet that for 10 consecutive business days, from August 27, 2025 to September 10, 2025, the company’s market value of listed securities was at or above $35,000,000. As a result, OneMedNet is again in compliance with Nasdaq Listing Rule 5550(b)(2), and Nasdaq considers the matter closed, allowing its common stock and warrants to remain listed on The Nasdaq Capital Market.